Morning Overview on MSN
FDA urges alternatives to animal testing in early-stage drug development
The U.S. Food and Drug Administration is actively steering drug developers away from traditional animal studies and toward human-biology-based testing methods for monoclonal antibody programs. The ...
The field of toxicology — determining whether a product is safe or harmful — is evolving rapidly. Many innovative drug safety technologies based on human biology, rather than the biology of other ...
MedPage Today on MSN
FDA proposes more flexibility in alternatives to animal testing in drug development
Non-animal testing methods could save drugmakers time and money, officials say ...
IVDR: where are we now in molecular testing? How IVDR implementation is progressing in molecular biology laboratories in different European countries IVDR, the new EU legislation for in-vitro ...
In April 2025, the FDA announced plans to shift biomedical research for monoclonal antibodies and other medications away from animal testing toward new approaches. One year later, much speculation ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sherlock Biosciences, an Engineering Biology company dedicated to making diagnostic testing better, faster and more affordable, today announced its launch and ...
Pharmacogenomic (PGx) testing is a growing area of personalized medicine with demonstrated clinical utility in improving patient outcomes in oncology. PGx testing of pharmacogenes affecting drug ...
Wrong! The editorial “End biology testing requirement” is all off. For most people, biology is more pertinent to their lives than algebra, geometry or calculus. Most of us will never need nor use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results